Form 4: Fulgent Genetics CSO Sells Shares for Tax

Fulgent Genetics' Chief Scientific Officer, Hanlin Gao, disposed of 1,642 shares of common stock to cover tax obligations related to restricted stock unit vesting.

Summary

• Hanlin Gao, Chief Scientific Officer of Fulgent Genetics, Inc. (FLGT), reported a transaction involving company common stock.
• On October 26, 2025, 1,642 shares of common stock were disposed of.
• This disposition was made to satisfy tax withholding obligations arising from the vesting of certain restricted stock units.
• The shares were valued at $23.74 per share for the purpose of this transaction.
• Following this transaction, Hanlin Gao directly beneficially owns 955,443 shares of common stock.
• The restricted stock units were assumed pursuant to an Agreement and Plan of Merger dated November 7, 2022, and were originally reported on a Form 4 filed on November 9, 2022.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While shares were disposed of, it was for a routine tax obligation following the vesting of restricted stock units, which is a positive event for the executive. It does not indicate any negative operational or financial news for the company.

Positives

• The vesting of restricted stock units indicates that the executive met performance or tenure conditions, which is generally a positive for executive compensation.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

This Form 4 filing is a routine disclosure of an insider transaction, specifically a tax-related disposition of shares following the vesting of equity compensation. Such transactions are common across all industries for executives receiving restricted stock units or other forms of equity-based compensation.

Stakeholder Impact

• Shareholders: The impact on shareholders is minimal, as this is a small, routine transaction for tax purposes and does not signal a change in the company's fundamentals or management's confidence.
• Executive (Hanlin Gao): The executive benefits from the vesting of restricted stock units, with the share disposition being a necessary step to fulfill tax liabilities.

Key Dates

Recommendation

This Form 4 filing details a routine tax-related disposition of shares by an executive following the vesting of restricted stock units. It provides no new information regarding Fulgent Genetics' operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate, as the filing itself does not present a compelling reason to buy or sell the stock.

Keywords

Fulgent Genetics, FLGT, insider trading, Form 4, stock sale, RSU vesting, tax withholding, Hanlin Gao, Chief Scientific Officer